129 related articles for article (PubMed ID: 6433462)
1. Haemophilia in children. Current immunologic status of a pediatric population.
Carnelli V; Giulotto P; Magnolfi C; Cordini M; Simoni L; Cultrera S; Bardare M
Scand J Haematol Suppl; 1984; 40():359-65. PubMed ID: 6433462
[No Abstract] [Full Text] [Related]
2. Immunologic studies in asymptomatic hemophiliac patients.
Frydecka I; Kowalewska B; Lesiecki A; Kuliczkowski K; Palakowska A; Polkowski A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):708-15. PubMed ID: 2435638
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against Australia-antigen in haemophilia.
Nordenfelt E; Nilsson IM
Rev Eur Etud Clin Biol; 1971 Feb; 16(2):151-5. PubMed ID: 5313698
[No Abstract] [Full Text] [Related]
4. How to manage invasive procedures in children with haemophilia.
Ljung RC; Knobe K
Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
[TBL] [Abstract][Full Text] [Related]
5. Alteration of T lymphocyte subpopulations in Swedish hemophiliacs.
Biberfeld G; Blombäck M; Egberg N; Lenkei R; Nilsson IM; Porwit-Ksiazek A
Scand J Haematol Suppl; 1984; 40():379-82. PubMed ID: 6332375
[No Abstract] [Full Text] [Related]
6. Immune complexes in hemophilia.
Poskitt TR; Poskitt PK; Bean CA; Arkel YS
Am J Hematol; 1981 Sep; 11(2):147-52. PubMed ID: 6795922
[TBL] [Abstract][Full Text] [Related]
7. The stimulation of immune antibodies anti-A and anti-B in patients after treatment with cryprecipitate and factor IX concentrate (P.P.S.B. according to Soulier).
McShine RL; Kunst VA
Vox Sang; 1970 May; 18(5):435-40. PubMed ID: 5311511
[No Abstract] [Full Text] [Related]
8. A study of cell mediated and humoral immunity in haemophilia and related disorders.
Moffat EH; Bloom AL; Jones J; Matthews N; Newcombe RG
Br J Haematol; 1985 Sep; 61(1):157-67. PubMed ID: 3931666
[TBL] [Abstract][Full Text] [Related]
9. Precipitating anti-VIII:C antibodies in two patients with haemophilia A.
Lavergne JM; Meyer D; Girma JP; Larrieu MJ
Br J Haematol; 1982 Jan; 50(1):135-46. PubMed ID: 6798988
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of various factor VIII concentrates used in treatment of haemophilia A.
Nilsson IM; Hedner U
Br J Haematol; 1977 Dec; 37(4):543-57. PubMed ID: 304740
[No Abstract] [Full Text] [Related]
11. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
Funk M; Ebener U; Kreuz W; Ehrenforth S
Lancet; 1993 Oct; 342(8876):933-4. PubMed ID: 7692198
[No Abstract] [Full Text] [Related]
12. Progress in the clinical management of haemophilia.
Bloom AL
Thromb Haemost; 1991 Jul; 66(1):166-77. PubMed ID: 1926047
[No Abstract] [Full Text] [Related]
13. AIDS surveillance in haemophilia.
Daly HM; Palmer R; Scott GL; Lee G
Br J Haematol; 1985 Feb; 59(2):383-90. PubMed ID: 3918559
[TBL] [Abstract][Full Text] [Related]
14. Current status and trends in the treatment of hemophilic patients with inhibitors.
Bloom AL
Prog Clin Biol Res; 1981; 72():123-38. PubMed ID: 6801682
[No Abstract] [Full Text] [Related]
15. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
[No Abstract] [Full Text] [Related]
16. Reactivity to factor-VIII concentrates of lymphocytes from patients with haemophilia and von Willebrand's disease.
Rossman RE; Brody JI
Br J Haematol; 1974 Sep; 28(1):131-6. PubMed ID: 4606982
[No Abstract] [Full Text] [Related]
17. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
18. [Immune coagulation disorders (excluding antiphospholipid syndrome].
Arai M
Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII-related antigen (VIII R:AG) in haemophilic patients and in carriers.
Bowie EJ; Fass DN
Lancet; 1979 Nov; 2(8151):1049-50. PubMed ID: 91786
[TBL] [Abstract][Full Text] [Related]
20. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
